VICARIOUS SURGICAL INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
VICARIOUS SURGICAL INC. (RBOT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 2.00 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-09
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 1.68M shares, a 12.70% increase year-over-year.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 1.72M shares, a 10.90% increase year-over-year.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 1.49M shares.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 1.55M shares, a 95.57% decline year-over-year.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 2.00M shares, a 17.33% increase from fiscal 2024.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 1.71M shares, a 12.32% increase from fiscal 2023.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 1.52M shares, a 95.74% decline from fiscal 2022.
- VICARIOUS SURGICAL INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 35.60M shares, a 10.22% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | 2.00M shares 10-K · filed 2026-03-09 | ||||||
| 2025-09-30 | 2.23M shares 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | 1.98M shares 10-Q · filed 2025-08-12 | ||||||
| 2025-03-31 | 1.68M shares 10-Q · filed 2025-05-12 | ||||||
| 2024-12-31 | 1.71M shares 10-K · filed 2026-03-09 | ||||||
| 2024-09-30 | 1.72M shares 10-Q · filed 2024-11-12 | 1.72M shares 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 1.79M shares 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | 1.49M shares 10-Q · filed 2025-05-12 | 44.78M shares 10-Q · filed 2024-04-29 | |||||
| 2023-12-31 | 1.52M shares 10-K · filed 2025-03-17 | 45.55M shares 10-K · filed 2024-03-04 | |||||
| 2023-09-30 | 1.55M shares 10-Q · filed 2024-11-12 | 46.60M shares 10-Q · filed 2023-11-13 | 1.54M shares 10-Q · filed 2024-11-12 | 46.16M shares 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | 35.60M shares 10-K · filed 2023-02-15 | ||||||
| 2022-09-30 | 35.04M shares 10-Q · filed 2023-11-13 | 34.69M shares 10-Q · filed 2022-11-07 | |||||
| 2022-06-30 | 31.31M shares 10-Q · filed 2022-08-08 | ||||||
| 2022-03-31 | 30.82M shares 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | 39.66M shares 10-K · filed 2022-03-31 | ||||||
| 2021-09-30 | 39.42M shares 10-Q/A · filed 2022-03-31 | 39.42M shares 10-Q/A · filed 2022-03-31 | |||||
| 2020-12-31 | 52.46M shares 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | 35.17M shares 10-Q/A · filed 2022-03-31 | 35.17M shares 10-Q/A · filed 2022-03-31 |